Vironexis Biotherapeutics Inc.
Clinical trials sponsored by Vironexis Biotherapeutics Inc., explained in plain language.
-
Gene therapy breakthrough targets Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis early-stage trial tests a new gene therapy called VNX-202 in 27 adults with HER2-positive solid tumors. The study aims to see if the treatment is safe and can shrink tumors or slow their growth. Participants must have advanced cancer that has worsened after standard treatmen…
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New gene therapy targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have come back or not responded to standard treatments. The study aims to find the safest dose and see if the therapy can control the cancer. Abo…
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated May 11, 2026 20:37 UTC